Le Lézard
Classified in: Health, Business
Subject: TNM

Avara Pharmaceutical Services acquires secondary solid dosage form manufacturing, packaging and distribution facility from AstraZeneca in France



NORWALK, Conn., Oct. 6, 2017 /PRNewswire/ -- Avara Pharmaceutical Services has signed and closed on an agreement with AstraZeneca to acquire the Reims, France manufacturing and distribution facility. "This key acquisition is another important component of our strategic plan that further expands our services," stated Timothy C. Tyson, Chairman and CEO.

Tim Tyson, a global leader in the pharmaceutical industry, is Chairman and CEO of Avara Pharmaceutical Services. In his 35-plus year career, Mr. Tyson has negotiated complex multi-billion dollar mergers and acquisitions, led major turn-arounds that have fueled growth and value and, most significantly, has been instrumental in bringing more than 50 lifesaving and life improving medicines to the market.

Avara Pharmaceutical Services is a state-of-the-art contract manufacturing and technical services organization providing both API formulation and manufacturing, along with secondary formulation, manufacturing, packaging and distribution of small molecule drugs, including highly potent compounds. Avara has secondary manufacturing technologies including granulation, coating, blending, encapsulation, compression and drying of tablets and capsules. Avara also has secondary sterile manufacturing capability in the Liscate site.

Welcoming the Reims team to Avara Pharmaceutical Services, the company now has eight sites: three in the US, including the corporate HQ's; one in Puerto Rico; one in the UK; one in Ireland; one in Italy and this new additional site in France.

1. Norwalk, CT (USA) - Corporate HQ 2. Arecibo, Puerto Rico -Development, Secondary manufacturing and packaging 3. Shannon, Ireland - Development and API formulation and manufacturing 4. Norman, OK (USA) -Development and Secondary manufacturing and packaging 5. Avlon, United Kingdom ?Development and API formulation and manufacturing 6. Liscate, Italy-Development and Sterile Manufacturing 7. Aiken, South Carolina?Secondary manufacturing and packaging 8. Reims, France ? Development and Secondary manufacturing, packaging and distribution

"With rapid expansion and integration set for 2017-2018, we continue, with great confidence, to build a pharmaceutical services company with complementary offerings in key regions to serve the rapidly growing market. Each site has significant professional experience, state of the art capability and a long history of delivering high quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements in every major market around the world. The people who are a part of the Avara team are the key to our long-term success," said Tyson.

About Avara

Avara Pharmaceutical Services, Inc., based in Norwalk, Connecticut is an international pharmaceutical services company that delivers world-class contract manufacturing and technical services to the pharmaceutical industry. Avara has development and primary and secondary manufacturing facilities in North America and Europe and supplies products to all major markets around the world. Avara's broad experience with supply chain, commercialization, product launch and product transfer allows us to sustain exemplary levels of product quality and regulatory compliance. The company is known to exceed customer service level expectations and consistently deliver on time, in full at a fair price. For more information, please visit our website at www.avara.com.

Contact: Guy Tiene, guy@thatsnice.com

Avara Pharmaceutical Services, Inc. (PRNewsfoto/Avara Pharmaceutical Services,)

SOURCE Avara Pharmaceutical Services, Inc.


These press releases may also interest you

at 11:40
A new article published today in The New England Journal of Medicine shows that 42 percent of diffuse large B cell lymphoma patients treated with axicabtagene ciloleucel, offered commercially under the brand name Yescartatm, remain in remission 15...

at 10:47
Novartis today announced updated results from the JULIET clinical trial demonstrating sustained responses with Kymriahtm (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, in adult patients with relapsed or refractory (r/r)...

at 10:30
For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta spotlight...

at 08:48
Four studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta highlight the multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality...

at 08:32
The number of variants identified as being associated with cancer risk and progression is rapidly growing. Meanwhile, advances in medical genomics are paving the way to novel approaches for the diagnosis, management, and treatment of patients with...

at 08:00
Blueprint Medicines Corporation , a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced new data from its ongoing Phase 1 clinical trial of avapritinib (formerly known as...




News published on 6 october 2017 at 12:12 and distributed by: